《2024年欧洲肝病学会临床实践指南:肝细胞癌管理》摘译  

An excerpt of EASL clinical practice guidelines on the management of hepatocellular carcinoma(2024 edition)

作　　者：杨嘉睿 江建新 YANG Jiarui;JIANG Jianxin(Department of Hepatobiliary Surgery,Dongguan People's Hospital,Dongguan,Guangdong 523000,China)

机构地区：[1]东莞市人民医院肝胆胰外科,广东东莞523000

出　　处：《临床肝胆病杂志》2025年第2期234-239,共6页Journal of Clinical Hepatology

摘　　要：肝癌是全球癌症相关死亡的第三大原因,其中肝细胞癌(HCC)约占原发性肝癌的90%。诊断和治疗技术的进步,以及对其临床应用的更深入理解,正在改变患者的治疗方式。将这些创新技术应用于临床实践中存在诸多挑战,亟需基于循证医学的规范化指导。新版临床实践指南通过系统评估最新研究数据,为HCC的诊疗管理提供了最新的建议。2024年欧洲肝病学会指南建议组建涵盖多学科专家的诊疗团队,通过多参数评估,从患者个体化需求出发,全面权衡治疗风险与临床获益。Liver cancer is the third leading cause of cancer-related deaths worldwide,among which hepatocellular carcinoma(HCC)accounts for approximately 90%in primary liver cancer.The advances in diagnostic and treatment tools,along with a deeper understanding of their application,are transforming the treatment modality for patients.The application of these innovations in clinical practice faces challenges and requires guidance,and related clinical practice guidelines provide the latest recommendations for the management of HCC patients and conduct a comprehensive review of related data.In the 2024 EASL guidelines,a multidisciplinary team from multiple specialties conducts a multi-parameter assessment of individual risks and benefits from the perspective of patients.

关 键 词：癌 肝细胞 欧洲 诊疗准则 

分 类 号：R73[医药卫生—肿瘤]